Transcatheter Perivascular Denervation
Ablative Solutions is developing a unique catheter-based approach for the treatment of hypertension. Delivered percutaneously, the Peregrine System™ Infusion Catheter offers controlled delivery of a neurolytic agent directly into the perivascular space with enhanced depth and area of denervation.
Commited to robust science, the company is undertaking a post-market study in Europe to further substantiate the procedural, clinical, and health-economic benefits of the Peregrine Catheter for the treatment of hypertension.
The company’s global TARGET BP I multi-center trial will also be initiated in European and US centers to evaluate the Peregrine Catheter and dehydrated alcohol (referred to as the Peregrine System Kit) for the treatment of persistent hypertension despite pharmacologic treatment, in conjunction with antihypertensive medical therapy.
Upcoming Events
CRT
March 2-5, 2019
Washington, DC
Interested in Learning more about Peregrine?
Ablative Solutions is currently enrolling patients in a post-market study in select regions regulated by the CE Mark. Click below for more information on the Peregrine Catheter and our European Clinical Studies.
Learn More
2013 All Rights Reserved
Suffering from High Blood Pressure?
Ablative Solutions is currently enrolling patients in a post-market study in select regions regulated by the CE Mark. A global Phase 2 clinical trial, TARGET BP I, for treatment of hypertension with combination drug/device therapy using the Peregrine System™ Kit will also be enrolling at select European sites.
Learn More
In the News
FDA Allows Ablative Solutions to Initiate its Phase 2 TARGET BP I Trial of Combination Drug/Device Therapy for Hypertension under its IND.
Learn More